Belantamab

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, GlaxoSmithKline Research Development Limited

Conditions

Autoimmune DiseasesCancerMultiple Myeloma

Phase 1

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

RecruitingNCT05714839

GlaxoSmithKlineMultiple Myeloma

Start: 2023-06-14End: 2028-08-03Target: 123Updated: 2026-08-19

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

WithdrawnNCT06413511

GlaxoSmithKlineAutoimmune Diseases

Start: 2024-06-03End: 2025-07-08Updated: 2025-08-27

Phase 2

?A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments.

Active, not recruitingPACTR202606758025670

GlaxoSmithKline Research Development LimitedCancer

Start: 2026-06-05Target: 8Updated: 2026-08-03

Related Papers

Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial.

Journal of Clinical Oncology2025-05-28

P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS

HemaSphere2023-08-011 citations